BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 25, 2004
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion
Amgen (AMGN) Friedman Billings Ramsey Jim Reddoch Downgrade Market perform (from market outperform)
Reddoch thinks that Medicare reimbursement changes next year will prompt cancer patients to receive certain treatments in the hospital rather than at a clinic. As a result, he lowered his 2005 sales estimates for cancer anemia drug Aranesp to $2.9 billion from $3.12 billion and for cancer neutropenia drug Neulasta to $2.07 billion from $2.22 billion. AMGN closed Friday at $52.70, down $2.52 on the week.
Antigenics (AGEN) Needham Mark Monane Downgrade Underperform (from hold)
Monane believes the company will need to...

Read the full 598 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >